Value of carcinoembryonec antigen in biochemotherapy response monitoring in patients with Her-2-positive advanced breast cancer / 南方医科大学学报
Journal of Southern Medical University
; (12): 1418-1421, 2010.
Article
在 Zh
| WPRIM
| ID: wpr-336163
Responsible library:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To assess the value of serum carcinoembryonec antigen (CEA) in monitoring the response to biochemotherapy by Herceptin plus taxol (TAX) in patients with Her-2-positive advanced breast cancer.</p><p><b>METHODS</b>The changes in serum CEA level were investigated retrospectively after two cycles of biochemotherapy in 83 patients with Her-2-positive advanced breast cancer. The correlations between the changes and radiological objective response were analyzed.</p><p><b>RESULTS</b>After two cycles of biochemotherapy, the clinical benefit rate (CBR) was 81.9%. In the 60 patients with lowered CEA level, the CBR was 85.0% (51/60), with a non-response rate of 15.0% (9/60); in contrast, the CBR was only 34.8% in 23 patients with elevated CEA, with a non-response rate of 65.2%, showing significant difference between the two groups (P<0.05).</p><p><b>CONCLUSION</b>Serum CEA level can be used to monitor the therapeutic effect of biochemotherapy in patients with Her-2-positive advanced breast cancer.</p>
全文:
1
索引:
WPRIM
主要主题:
Blood
/
Breast Neoplasms
/
Antineoplastic Combined Chemotherapy Protocols
/
Carcinoembryonic Antigen
/
Paclitaxel
/
Receptor, ErbB-2
/
Therapeutic Uses
/
Drug Therapy
/
Antibodies, Monoclonal, Humanized
/
Trastuzumab
限制:
Adult
/
Aged
/
Female
/
Humans
语言:
Zh
期刊:
Journal of Southern Medical University
年:
2010
类型:
Article